Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Period	dileps
2014-12-31	N/A
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	N/A
2021-12-31	-$0.81
2022-12-31	-$1.69
2023-12-31	-$1.69
2024-12-31	-$1.56

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENLV	$0.93	+11.11%	1.43M
3
4
5

Enlivex Therapeutics Ltd. (ENLV) Earnings Per Share (EPS)

EPS (Earnings Per Share) Data

Get Enlivex Therapeutics Ltd. Data in Excel

More ENLV Financial Data